ALSO NOTED: Dr. Reddy's takes a gamble on biogenerics; Coley receives $5M from Dynavax; and much more...

> Brian Orelli of the Motley Fool profiles a risky move by generic drugmaker Dr. Reddy's Laboratories. Article [1]

> In New Jersey, the biotech industry is booming. Article [2]

> Coley will receive at least $5 million from Dynavax Technologies for the nonexclusive marketing rights to commercialize Coley's hepatitis B vaccine Heplisav. The therapy is in late-stage trials. Release [3]

> Keryx Biopharmaceuticals presented positive data on the clinical activity of KRX-0401 (perifosine) in patients with advanced multiple myeloma and Waldenstrom's macroglobulinemia. Release [4]

> An expert panel has delayed a decision on endorsing FluMist for children under 5, a move that will likely close that market to MedImmune for the upcoming flu season. Report [5]

> The European Commission has granted Merck KGaA marketing approval for its fertility drug Pergoveris. Report [6]

> France's NicOx has begun its third pivotal Phase III clinical trial for naproxcinod in patients with osteoarthritis of the hip. Release [7]

And Finally... Research shows that exercise creates new brain cells. Release [8]